Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis
NCT ID: NCT01093326
Last Updated: 2025-03-30
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
353 participants
INTERVENTIONAL
2010-05-12
2023-09-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis
NCT03232073
Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis
NCT02425644
Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis
NCT01006265
Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
NCT01464905
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
NCT01081782
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ponesimod 10 mg
Ponesimod 10 mg oral use
Ponesimod 10 mg
Ponesimod 10 mg oral use
Ponesimod 20 mg
Ponesimod 20 mg oral use
Ponesimod 20 mg
Ponesimod 20 mg oral use
Ponesimod 40 mg
Ponesimod 40 mg oral use
Ponesimod 40 mg
Ponesimod 40 mg oral use
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ponesimod 10 mg
Ponesimod 10 mg oral use
Ponesimod 20 mg
Ponesimod 20 mg oral use
Ponesimod 40 mg
Ponesimod 40 mg oral use
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Signed informed consent for participating in the extension study.
Exclusion Criteria
18 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Actelion
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Phoenix, Arizona, United States
Scottsdale, Arizona, United States
Palo Alto, California, United States
Sacramento, California, United States
Venice, Florida, United States
Indianapolis, Indiana, United States
Kansas City, Kansas, United States
Lenexa, Kansas, United States
Latham, New York, United States
Schenectady, New York, United States
Stony Brook, New York, United States
Raleigh, North Carolina, United States
Cincinnati, Ohio, United States
Columbus, Ohio, United States
Burlington, Vermont, United States
Kirkland, Washington, United States
Vienna, , Austria
Sofia, , Bulgaria
Ottawa, Ontario, Canada
Brno, , Czechia
Jihlava, , Czechia
Olomouc, , Czechia
Ostrava-Poruba, , Czechia
Prague, , Czechia
Teplice, , Czechia
Helsinki, , Finland
Hyvinkää, , Finland
Tampere, , Finland
Turku, , Finland
Montpellier, , France
Berlin, , Germany
Essen, , Germany
Ulm, , Germany
Budapest, , Hungary
Esztergom, , Hungary
Győr, , Hungary
Miskolc, , Hungary
Tel Litwinsky, , Israel
Ẕerifin, , Israel
Breda, , Netherlands
Katowice, , Poland
Poznan, , Poland
Warsaw, , Poland
Wroclaw, , Poland
Cluj-Napoca, , Romania
Timișoara, , Romania
Kazan', , Russia
Moscow, , Russia
Nizhny Novgorod, , Russia
Pyatigorsk, , Russia
Saint Petersburg, , Russia
Samara, , Russia
Saratov, , Russia
Ufa, , Russia
Belgrade, , Serbia
Kragujevac, , Serbia
Niš, , Serbia
Majadahonda, , Spain
Málaga, , Spain
Seville, , Spain
Gothenburg, , Sweden
Stockholm, , Sweden
Umeå, , Sweden
Lugano, , Switzerland
Chernihiv, , Ukraine
Dnipropetrovsk, , Ukraine
Kyiv, , Ukraine
Odesa, , Ukraine
Bristol, , United Kingdom
London, , United Kingdom
Plymouth, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2009-011470-15
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
AC-058B202
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.